ReviewFrontiers in endocrinology2020
Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments.
Review in Frontiers in endocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 133 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
133 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Persevering or quitting? A systematic review of adherence and dropout in nutrition and exercise interventions for sarcopenic obesity.Asia Pacific journal of clinical nutrition · 2026Pooled it
- Prevalence of sarcopenic obesity in adult patients with diabetes and associated factors: a systematic review and meta-analysis.Frontiers in nutrition · 2026Pooled it
- Pooled it
- Bibliometric mapping of diabetes mellitus and sarcopenia research: hotspots and emerging trends.Frontiers in medicine · 2025Pooled it
- Effects of non-pharmacological interventions on patients with sarcopenic obesity: A meta-analysis.PloS one · 2023Pooled it
- Pooled it
- Synergistic effects of synbiotic, protein supplementation, and resistance training on inflammation, oxidative stress, and muscle strength in older adults with type 2 diabetes mellitus: a RCT triple-blinded study.European journal of nutrition · 2026Trial
- Changes in Choline Metabolites and Ceramides in Response to a DASH-Style Diet in Older Adults.Nutrients · 2023Trial
- Establishment and evaluation of a novel practical tool for the diagnosis of pre-sarcopenia in young people with diabetes mellitus.Journal of translational medicine · 2023Trial
- Endocrinological aspects of sarcopenic obesity.Annals of medicine · 2026Review
- Low Free Testosterone Is Independently Associated With Long-Term Mortality in Men With Chronic Spinal Cord Injury.Andrology · 2026Article
- Nanoparticles for autoimmune diseases: advancing diagnostics and therapeutic solutions.Acta pharmacologica Sinica · 2026Review
- Gan-Mai-Da-Zao-Tang attenuates age-induced skeletal muscle wasting and improves mitochondrial function in mice.Journal of traditional and complementary medicine · 2026Article
- Association Between Serum Creatinine to Cystatin C Ratio and Activities of Daily Living Disability Trajectories: Evidence From the China Health and Retirement Longitudinal Study.Geriatrics & gerontology international · 2026Article
- Prevalence and risk factors of sarcopenic obesity in Thai people with diabetes: A cross-sectional study.Obesity pillars · 2026Article
- Lifestyle intervention outcomes in T2DM and the added value of CGM: 6-month results from the Polish cohort of the C4D study.Scientific reports · 2026Article
- The role of CXCL10 in high-fat diet-induced skeletal muscle inflammation and atrophy.Journal of diabetes investigation · 2026Article
- Switching from insulin injections to degludec/liraglutide in older frail persons: 6-month body composition remodelling.European geriatric medicine · 2026Article
- Obesity in Type 1 Diabetes: Moving Beyond the "Lean" Disease Paradigm to Understand Risk, Complications, and Treatment.Current obesity reports · 2026Review
- The Landscape of SERCA2 in Cardiovascular Diseases: Expression Regulation, Therapeutic Applications, and Emerging Roles.Biomolecules · 2026Review
73 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenic obesity and diabetes are two increasing health problems worldwide, which both share many common risk factors, such as aging, and general obesity. The pathogenesis of sarcopenic obesity includes aging, physical inactivity, malnutrition, low-grade inflammation, insulin resistance, and hormonal changes. Nevertheless, there are two major reasons to cause diabetes: impaired insulin secretion and impaired insulin action. Furthermore, the individual diagnosis of obesity and sarcopenia should be combined to adequately define sarcopenic obesity. Also, the diagnosis of diabetes includes fasting plasma glucose test (FPG), 2-h oral glucose tolerance test (OGTT), glycated hemoglobin (A1C), and random plasma glucose coupled with symptoms. Healthy diet and physical activity are beneficial to both sarcopenic obesity and diabetes, but there are only recommended drugs for diabetes. This review consolidates and discusses the latest research in pathogenesis, diagnosis, and treatments of diabetes and sarcopenic obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.